These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17634557)

  • 1. Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition.
    Zhou Q; Guo P; Kruh GD; Vicini P; Wang X; Gallo JM
    Clin Cancer Res; 2007 Jul; 13(14):4271-9. PubMed ID: 17634557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic model-predicted anticancer drug concentrations in human tumors.
    Gallo JM; Vicini P; Orlansky A; Li S; Zhou F; Ma J; Pulfer S; Bookman MA; Guo P
    Clin Cancer Res; 2004 Dec; 10(23):8048-58. PubMed ID: 15585640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients.
    Rosso L; Brock CS; Gallo JM; Saleem A; Price PM; Turkheimer FE; Aboagye EO
    Cancer Res; 2009 Jan; 69(1):120-7. PubMed ID: 19117994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models.
    Ma J; Li S; Reed K; Guo P; Gallo JM
    J Pharmacol Exp Ther; 2003 Jun; 305(3):833-9. PubMed ID: 12626639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470.
    Ma J; Pulfer S; Li S; Chu J; Reed K; Gallo JM
    Cancer Res; 2001 Jul; 61(14):5491-8. PubMed ID: 11454697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens.
    Zhou Q; Guo P; Wang X; Nuthalapati S; Gallo JM
    J Pharmacol Exp Ther; 2007 Apr; 321(1):265-75. PubMed ID: 17259446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study.
    Wei KC; Chu PC; Wang HY; Huang CY; Chen PY; Tsai HC; Lu YJ; Lee PY; Tseng IC; Feng LY; Hsu PW; Yen TC; Liu HL
    PLoS One; 2013; 8(3):e58995. PubMed ID: 23527068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases.
    Hoffmann J; Fichtner I; Lemm M; Lienau P; Hess-Stumpp H; Rotgeri A; Hofmann B; Klar U
    Neuro Oncol; 2009 Apr; 11(2):158-66. PubMed ID: 18780814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of an adenosine A
    Jackson S; Weingart J; Nduom EK; Harfi TT; George RT; McAreavey D; Ye X; Anders NM; Peer C; Figg WD; Gilbert M; Rudek MA; Grossman SA
    Fluids Barriers CNS; 2018 Jan; 15(1):2. PubMed ID: 29332604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients.
    Ostermann S; Csajka C; Buclin T; Leyvraz S; Lejeune F; Decosterd LA; Stupp R
    Clin Cancer Res; 2004 Jun; 10(11):3728-36. PubMed ID: 15173079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain.
    Jackson S; Anders NM; Mangraviti A; Wanjiku TM; Sankey EW; Liu A; Brem H; Tyler B; Rudek MA; Grossman SA
    J Neurooncol; 2016 Feb; 126(3):433-9. PubMed ID: 26626489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470.
    Devineni D; Klein-Szanto A; Gallo JM
    Cancer Res; 1996 May; 56(9):1983-7. PubMed ID: 8616836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates.
    Patel M; McCully C; Godwin K; Balis FM
    J Neurooncol; 2003 Feb; 61(3):203-7. PubMed ID: 12675312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC.
    Kirstein MN; Panetta JC; Gajjar A; Nair G; Iacono LC; Freeman BB; Stewart CF
    Cancer Chemother Pharmacol; 2005 May; 55(5):433-8. PubMed ID: 15818507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temozolomide and treatment of malignant glioma.
    Friedman HS; Kerby T; Calvert H
    Clin Cancer Res; 2000 Jul; 6(7):2585-97. PubMed ID: 10914698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation.
    Portnow J; Badie B; Chen M; Liu A; Blanchard S; Synold TW
    Clin Cancer Res; 2009 Nov; 15(22):7092-8. PubMed ID: 19861433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic activation of temozolomide measured in vivo using positron emission tomography.
    Saleem A; Brown GD; Brady F; Aboagye EO; Osman S; Luthra SK; Ranicar AS; Brock CS; Stevens MF; Newlands E; Jones T; Price P
    Cancer Res; 2003 May; 63(10):2409-15. PubMed ID: 12750260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats.
    Heimberger AB; Archer GE; McLendon RE; Hulette C; Friedman AH; Friedman HS; Bigner DD; Sampson JH
    Clin Cancer Res; 2000 Oct; 6(10):4148-53. PubMed ID: 11051269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.
    Middlemas DS; Stewart CF; Kirstein MN; Poquette C; Friedman HS; Houghton PJ; Brent TP
    Clin Cancer Res; 2000 Mar; 6(3):998-1007. PubMed ID: 10741727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors.
    Panetta JC; Kirstein MN; Gajjar A; Nair G; Fouladi M; Heideman RL; Wilkinson M; Stewart CF
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):435-41. PubMed ID: 13680158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.